CADILLAC Trial

BySteven Lome, MD

Trial Details:

Acronym: Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications

Purpose: To evaluate abciximab (Reopro) when added to ticlopidine and aspirin during coronary intervention in acute coronary syndromes.

Format: Double blind, multicenter, randomized control trial

Treatment Group: Abciximab and percutaneous coronary intervention (PCI)

Control Group: Percutaneous coronary intervention alone

Number of Patients: 2,082

Inclusion Criteria:

Clinical angina or other symptoms from acute coronary syndrome for < 12 hours
ECG with > 1 mm ST elevation in 2 contiguous leads OR high grade stenosis on angiography with an associated regional wall motion abnormality

Exclusion Criteria:

Cardiogenic shock
Infarct due to saphenous vein graft occlusion/stenosis
Infarct artery reference vessel < 2.5 mm in diameter
Need for urgent r emergent coronary artery bypass grafting surgically

Follow-up: 7-12 months

Primary Endpoint: Composite of all cause mortality, MI, ischemia-driven target-vessel revascularization (TVR), or stroke at 30 days

Summary:

Abciximab decreased mortality and target vessel revascularization when used in addition to ticlopidine and aspirin during percutaneous coronary intervention in the setting of an acute coronary syndrome.

Original Publication:

Tcheng JE, et al. Circulation. 2003 Sep 16;108(11):1316-23.